Novel Blood Thinner Shows Promise in Atrial Fibrillation

TOPLINE:  In the OCEANIC-AF trial, asundexian resulted in lower rates of stroke and bleeding than apixaban in patients with atrial fibrillation (AF) who were naive to oral anticoagulants. METHODOLOGY: In the prespecified exploratory subgroup analysis of the OCEANIC-AF randomized clinical trial, the researchers evaluated 14,810 patients with AF who were enrolled across 1035 sites in …